Myomo, Inc. (MYO)
USD 4.88
(2.95%)
USD 4.88
(2.95%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 19.24 Million USD | 23.7% |
| 2022 | 15.55 Million USD | 12.26% |
| 2021 | 13.85 Million USD | 82.72% |
| 2020 | 7.58 Million USD | 97.6% |
| 2019 | 3.83 Million USD | 57.02% |
| 2018 | 2.44 Million USD | 56.79% |
| 2017 | 1.55 Million USD | 41.29% |
| 2016 | 1.1 Million USD | 59.97% |
| 2015 | 689.67 Thousand USD | -24.48% |
| 2014 | 913.25 Thousand USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 3.75 Million USD | -21.07% |
| 2024 Q2 | 7.52 Million USD | 100.32% |
| 2023 FY | 19.24 Million USD | 23.7% |
| 2023 Q3 | 5.07 Million USD | -14.75% |
| 2023 Q1 | 3.44 Million USD | -14.72% |
| 2023 Q4 | 4.75 Million USD | -6.36% |
| 2023 Q2 | 5.95 Million USD | 72.88% |
| 2022 Q2 | 3.67 Million USD | -4.92% |
| 2022 Q1 | 3.86 Million USD | -4.06% |
| 2022 FY | 15.55 Million USD | 12.26% |
| 2022 Q4 | 4.04 Million USD | 1.85% |
| 2022 Q3 | 3.96 Million USD | 7.9% |
| 2021 Q4 | 4.03 Million USD | -8.04% |
| 2021 Q2 | 3.1 Million USD | 32.86% |
| 2021 Q1 | 2.33 Million USD | -38.35% |
| 2021 FY | 13.85 Million USD | 82.72% |
| 2021 Q3 | 4.38 Million USD | 41.22% |
| 2020 FY | 7.58 Million USD | 97.6% |
| 2020 Q2 | 858.59 Thousand USD | -14.83% |
| 2020 Q3 | 1.92 Million USD | 124.4% |
| 2020 Q4 | 3.78 Million USD | 96.71% |
| 2020 Q1 | 1 Million USD | -33.71% |
| 2019 Q4 | 1.52 Million USD | 150.68% |
| 2019 FY | 3.83 Million USD | 57.02% |
| 2019 Q3 | 606.61 Thousand USD | -31.09% |
| 2019 Q2 | 880.34 Thousand USD | 6.06% |
| 2019 Q1 | 830.06 Thousand USD | -6.69% |
| 2018 Q1 | 313.17 Thousand USD | -42.79% |
| 2018 Q4 | 889.57 Thousand USD | 46.08% |
| 2018 FY | 2.44 Million USD | 56.79% |
| 2018 Q2 | 632.36 Thousand USD | 101.92% |
| 2018 Q3 | 608.98 Thousand USD | -3.7% |
| 2017 Q2 | 306.68 Thousand USD | 41.83% |
| 2017 Q1 | 216.23 Thousand USD | -51.74% |
| 2017 Q3 | 488.54 Thousand USD | 59.3% |
| 2017 Q4 | 547.41 Thousand USD | 12.05% |
| 2017 FY | 1.55 Million USD | 41.29% |
| 2016 Q4 | 448.09 Thousand USD | 143.27% |
| 2016 Q2 | 254.07 Thousand USD | 17.13% |
| 2016 Q3 | 184.19 Thousand USD | -27.5% |
| 2016 Q1 | 216.92 Thousand USD | 55.08% |
| 2016 FY | 1.1 Million USD | 59.97% |
| 2015 FY | 689.67 Thousand USD | -24.48% |
| 2015 Q1 | 204.95 Thousand USD | 0.0% |
| 2015 Q4 | 139.88 Thousand USD | 0.0% |
| 2015 Q3 | 139.88 Thousand USD | -31.75% |
| 2015 Q2 | 204.95 Thousand USD | 0.0% |
| 2014 FY | 913.25 Thousand USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Abbott Laboratories | 40.1 Billion USD | 99.952% |
| Allurion Technologies Inc. | 53.46 Million USD | 64.013% |
| Artivion, Inc. | 354 Million USD | 94.565% |
| Avanos Medical, Inc. | 673.3 Million USD | 97.142% |
| Butterfly Network, Inc. | 65.9 Million USD | 70.802% |
| Butterfly Network, Inc. | 65.9 Million USD | 70.802% |
| Bio-Rad Laboratories, Inc. | 2.67 Billion USD | 99.28% |
| Boston Scientific Corporation | 14.24 Billion USD | 99.865% |
| CONMED Corporation | 1.24 Billion USD | 98.449% |
| Edwards Lifesciences Corporation | 6 Billion USD | 99.68% |
| Paragon 28, Inc. | 216.38 Million USD | 91.108% |
| Glaukos Corporation | 314.71 Million USD | 93.886% |
| Globus Medical, Inc. | 1.56 Billion USD | 98.773% |
| Inspire Medical Systems, Inc. | 624.79 Million USD | 96.92% |
| Integer Holdings Corporation | 1.59 Billion USD | 98.795% |
| Medtronic plc | 32.36 Billion USD | 99.941% |
| Nevro Corp. | 425.17 Million USD | 95.475% |
| Owlet, Inc. | 54.01 Million USD | 64.375% |
| Penumbra, Inc. | 1.05 Billion USD | 98.182% |
| Vicarious Surgical Inc. | - USD | -Infinity% |
| Smith & Nephew plc | 5.54 Billion USD | 99.653% |
| STERIS plc | 5.13 Billion USD | 99.626% |
| Stryker Corporation | 20.49 Billion USD | 99.906% |
| Vapotherm, Inc. | 68.66 Million USD | 71.98% |
| Zimmer Biomet Holdings, Inc. | 7.39 Billion USD | 99.74% |